BTK and B-cell chronic lymphocytic leukemia: Bruton's tyrosine kinase (BTK) inhibitors have transformed the treatment landscape of CLL, but their role in RT is less well defined.<h4>Methods</h4>We conducted a systematic review in accordance with PRISMA guidelines to evaluate the efficacy and safety of BTK inhibitor-based therapies in patients with RT.